Z-LEHD-fmk Options
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To guage many intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Principal demo targets were being to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyos